cas 850663-54-6|| where to buy 4-Chloro-2-hydroxy-5-nitropyridine

Produktname:4-Chloro-2-hydroxy-5-nitropyridine

IUPAC Name:4-chloro-5-nitropyridin-2-ol

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM116864-10g	in stock	ǯŢ
CM116864-25g	in stock	ȎǊȀ
CM116864-100g	in stock	źȀư

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 850663-54-6 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:850663-54-6; Molekulare Formel:C5H3ClN2O3; Schmelzpunkt:-; SMILES-Code:O=[N+](C1=CN=C(O)C=C1Cl)[O-]; Dichte:

: Katalognummer:CM116864; Molekulargewicht:174.54; Siedepunkt:; Mdl-Nr.:MFCD11046303; Lagerung:Keep in inert atmosphere, store in freezer, under -20°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Elinzanetant; On January 8, 2024, Bayer announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully met all four primary endpoints and all three key secondary endpoints in both studies. Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist for the non-hormonal treatment of moderate to severe VMS associated with menopause. Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen, become hypertrophic and lead to a hyperactivation of the thermoregulatory pathway, consequently disrupting body heat control mechanisms resulting in VMS. Elinzanetant may also decrease sleep disturbances associated with menopause.